There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Haemonetics Corp (NYSE: HAE) and Alder Biopharmaceuticals (NASDAQ: ALDR) with bullish sentiments.
Haemonetics Corp (NYSE: HAE)
Barrington analyst Michael Petusky maintained a Buy rating on Haemonetics Corp (NYSE: HAE) today and set a price target of $90. The company’s shares closed yesterday at $82.55, close to its 52-week high of $82.70.
Petusky wrote:
“We are maintaining our OUTPERFORM investment rating on HAE shares given the solid fourth quarter result, the strong FY/19 financial guidance, and our increasing confidence that the company is executing against its key strategic goals. Our price target is now $90 (up from $71) and is based on attaching a 20x multiple to our adjusted EBITDA estimate for FY/19. We assume $50 million in net debt 12 months from now.”
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 12.1% and a 60.5% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.
Currently, the analyst consensus on Haemonetics Corp is Moderate Buy and the average price target is $95, representing a 15.1% upside.
In a report released today, Morgan Stanley also maintained a Buy rating on the stock with a $100 price target.
See today’s analyst top recommended stocks >>
Alder Biopharmaceuticals (NASDAQ: ALDR)
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Alder Biopharmaceuticals (NASDAQ: ALDR), with a price target of $29. The company’s shares closed yesterday at $14.
Yang wrote:
“We expect Alder will likely require another round of capital raising to commercialize Eptinezumab.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 20.2% and a 50.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Audentes Therapeutics, and Revance Therapeutics.
Currently, the analyst consensus on Alder Biopharmaceuticals is Strong Buy and the average price target is $22.67, representing a 61.9% upside.
In a report released today, BMO Capital also maintained a Buy rating on the stock with a $21 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
